Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
- PMID: 23176083
- PMCID: PMC3674614
- DOI: 10.1186/ar4099
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
Abstract
Introduction: Clinical trials have demonstrated that treatment-to-target (T2T) is effective in achieving remission in early rheumatoid arthritis (RA). However, the concept of T2T has not been fully implemented yet and the question is whether a T2T strategy is feasible in daily clinical practice. The objective of the study was to evaluate the adherence to a T2T strategy aiming at remission (Disease Activity Score in 28 joints (DAS28) < 2.6) in early RA in daily practice. The recommendations regarding T2T included regular assessment of the DAS28 and advice regarding DAS28-driven treatment adjustments.
Methods: A medical chart review was performed among a random sample of 100 RA patients of the DREAM remission induction cohort. At all scheduled visits, it was determined whether the clinical decisions were compliant to the T2T recommendations.
Results: The 100 patients contributed to a total of 1,115 visits. The DAS28 was available in 97.9% (1,092/1,115) of the visits, of which the DAS28 was assessed at a frequency of at least every three months in 88.3% (964/1,092). Adherence to the treatment advice was observed in 69.3% (757/1,092) of the visits. In case of non-adherence when remission was present (19.5%, 108/553), most frequently medication was tapered off or discontinued when it should have been continued (7.2%, 40/553) or treatment was continued when it should have been tapered off or discontinued (6.2%, 34/553). In case of non-adherence when remission was absent (42.1%, 227/539), most frequently medication was not intensified when an intensification step should have been taken (34.9%, 188/539). The main reason for non-adherence was discordance between disease activity status according to the rheumatologist and DAS28.
Conclusions: The recommendations regarding T2T were successfully implemented and high adherence was observed. This demonstrates that a T2T strategy is feasible in RA in daily clinical practice.
Figures
Similar articles
-
The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.Arthritis Res Ther. 2019 Jul 5;21(1):164. doi: 10.1186/s13075-019-1937-4. Arthritis Res Ther. 2019. PMID: 31277720 Free PMC article.
-
Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.Arthritis Rheum. 2011 Oct;63(10):2865-72. doi: 10.1002/art.30494. Arthritis Rheum. 2011. PMID: 21647867
-
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227. Arthritis Rheum. 2010. PMID: 20039405
-
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420. Health Technol Assess. 2006. PMID: 17049139 Review.
-
Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6. Semin Arthritis Rheum. 2013. PMID: 23838092 Review.
Cited by
-
Achieving osteoporosis treat-to-target goals with teriparatide or alendronate: sub-analysis of Japanese Osteoporosis Intervention Trial-05 (JOINT-05).J Bone Miner Metab. 2024 May;42(3):382-388. doi: 10.1007/s00774-024-01515-5. Epub 2024 May 16. J Bone Miner Metab. 2024. PMID: 38755328 Free PMC article. Clinical Trial.
-
Adherence to Subcutaneous Anti-Tumour Necrosis Factor Treatment in a Cohort of Patients with Rheumatoid Arthritis Before and After the Implementation of a Comprehensive Care Model.Biologics. 2022 Nov 21;16:199-209. doi: 10.2147/BTT.S385422. eCollection 2022. Biologics. 2022. PMID: 36440060 Free PMC article.
-
Management of rheumatoid arthritis in Poland - where daily practice might not always meet evidence-based guidelines.Arch Med Sci. 2019 Mar 29;17(5):1286-1293. doi: 10.5114/aoms.2019.84092. eCollection 2021. Arch Med Sci. 2019. PMID: 34522257 Free PMC article.
-
Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry.Arthritis Care Res (Hoboken). 2023 Feb;75(2):231-239. doi: 10.1002/acr.24762. Epub 2022 Sep 10. Arthritis Care Res (Hoboken). 2023. PMID: 34338449 Free PMC article.
-
Disease-modifying antirheumatic drug prescription patterns in adult rheumatoid arthritis patients in routine clinical practice in Spain.Eur J Rheumatol. 2020 Sep 3;7(4):149-57. doi: 10.5152/eurjrheum.2020.19053. Online ahead of print. Eur J Rheumatol. 2020. PMID: 32910753 Free PMC article.
References
-
- Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G. et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;14:964–975. doi: 10.1136/ard.2009.126532. - DOI - PMC - PubMed
-
- Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) Ann Rheum Dis. 2007;14:1443–1449. doi: 10.1136/ard.2007.071092. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
